Trials / Withdrawn
WithdrawnNCT02887534
Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain
A Randomized, Double-blind, Active and Placebo-controlled, Study of SPARC1401 in Subjects With Moderate to Severe Acute Low Back Pain
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sun Pharma Advanced Research Company Limited · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2 randomized clinical trial to evaluate efficacy and safety of SPARC1401 at three dose levels in patients with acute low back pain
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPARC1401-low dose | SPARC1401- low dose |
| DRUG | SPARC1401-mid dose | SPARC1401- mid dose |
| DRUG | SPARC1401-high dose | SPARC1401-high dose |
| DRUG | Reference1401 (Tizanidine) | Reference1401 (Tizanidine) three times a day |
| DRUG | Placebo1401 | Placebo |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2016-09-02
- Last updated
- 2019-05-03
Source: ClinicalTrials.gov record NCT02887534. Inclusion in this directory is not an endorsement.